The Neurotrophins Market is expected to register a CAGR of 7% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The research report on the neurotrophins market is segmented by product type into nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and others. Applications analyzed include neurodegenerative disorders, mental health conditions, and others. End-users covered in the study are pharmaceutical and biotechnology companies, academic and research institutes, and hospitals. The global analysis is broken down by region and key countries, covering North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses.
Purpose of the ReportThe report Neurotrophins Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Neurotrophins Market Segmentation
Product Type- Nerve Growth Factor
- Brain-Derived Neurotrophic Factor
- Dehydroepiandrosterone Sulfate
- Alzheimer's Disease
- Amyotrophic Lateral Sclerosis
- Parkinson's Disease
- Hospitals
- Diagnostic Centers
Strategic Insights
Neurotrophins Market Growth Drivers- Increased Neurological disorders globally: One of the most prominent drivers for the neurotrophin market is the global increase in neurological disorders. The World Health Organization (WHO) states that 50 million people worldwide are affected by dementia, and 60-70% of those cases are due to Alzheimer's disease. Parkinson's disease affects about 10 million people worldwide, and these numbers are likely to double by 2040. These numbers are likely to increase significantly with the population's aging. Neurodegenerative diseases are now among the leading causes of death, and neurodegenerative diseases are the second most common cause of death in high-income countries, according to a report by Lancet Neurology. Neurotrophins, which include nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), are being intensively researched for the slowing of disease progression and the promotion of neuron survival. Given the increasing population suffering from such disorders, neurotrophin-based treatments are likely to be in growing demand.
- Advances in Biotechnology: Biotechnology has been instrumental in propelling the neurotrophins market. Recent breakthroughs in gene therapy, stem cell therapy, and drug delivery systems have opened up new avenues for the use of neurotrophins in the treatment of neurological disorders. One of the key examples of this is the use of viral vectors in gene therapy to deliver neurotrophin genes to the central nervous system. Grand View Research estimates that the gene therapy market around the world is expected to register a compound annual growth rate of 25.3%, and it would reach a size of $13.9 billion by 2028. Advanced biotechnological approaches to stabilize neurotrophins and improve their bioavailability create new avenues of treatment for neurodegenerative disorders such as Alzheimer's and Parkinson's. With the reduction of delivery barriers through technological advancements, the scope for effective treatments using neurotrophins is expanding, which is driving market growth.
- Aging Population: The global aging population is a significant contributor to the demand for neurotrophin-based therapies. According to the United Nations, by 2050, 1 in 6 people on Earth will be aged 60 or over. The elderly are, in particular, easy targets for various neurological diseases since Alzheimer's diseases and other dementia conditions have made 1 of every 10 people older than 65 within the United States, according to the reports from the Alzheimer's Association. The prevalence of dementia is expected to increase from 55 million in 2020 to 139 million by 2050. Neurotrophins, which have been known to support the growth and survival of neurons, have shown promise in combating neurodegenerative diseases, making them a valuable therapeutic tool. With an aging global population, the promise of neurotrophin-based therapies holds promise as a treatment to delay or reverse cognitive decline, which will drive demand into huge market opportunities.
- Targeted Therapies: Targeted therapies are becoming the new trend in the neurotrophins market, as they offer more precision and fewer side effects than traditional treatments. Neurotrophins, such as NGF and BDNF, are being researched for their potential to target specific neuronal pathways and promote neuroprotection in targeted regions of the brain. The precision medicine market, which is closely linked to targeted therapies, is projected to reach $81.8 billion by 2025, according to a report by MarketsandMarkets. The trend towards precision medicine reflects a shift away from one-size-fits-all approaches and toward treatments that are tailored to the individual patient's genetic makeup, disease subtype, and treatment response. In neurologic diseases, neurotrophin-targeted therapies may safeguard injured neurons, thereby decelerating disease progression, improving patient prognosis. This aspect of specificity is creating a buzz for neurotrophin-based therapy in the market.
- Integration with Gene Therapy: Neurotrophin-based treatments have lately been taken along with gene therapy. In this therapy, the genes coding for neurotrophins can be introduced to cells of the patient to continuously release neurotrophins. Gene therapy, according to the World Health Organization, will rapidly grow; hence, a 26.4% CAGR between 2023 and 2030 is expected. This has the possibility of long-term production of neurotrophin with no limit posed by the half-life of administered neurotrophins or by the inability to cross the blood-brain barrier. Several companies are already exploring viral vectors, nanoparticles, and other gene delivery systems to enhance the delivery of neurotrophins to the brain, particularly in the treatment of neurodegenerative diseases. This innovative trend is expected to create new treatment options for patients and boost the adoption of neurotrophin-based therapies.
- Biomarker Identification: Biomarker identification in the neurotrophins market is essential for early diagnosis, disease progression monitoring, and assessing therapeutic efficacy. Currently, over 6 million Americans have Alzheimer's. Early detection makes any treatment effective because the disease impacts the brain much earlier than apparent symptoms. Other neurotrophic factors, particularly BDNF, have come to be discovered as potential Alzheimer's or neurodegenerative disease biomarkers. Cognitive decline has a correlation with less BDNF, which puts it as the potential early Alzheimer's marker. Advances in diagnostic tools and rising awareness among clinicians about biomarkers, including neurotrophins, will be crucial for earlier diagnosis, personalization of treatment plans, and better patient responses. This trend is bettering disease management and helping the neurotrophins market grow because companies are now more interested in the integration of biomarkers into diagnostic as well as therapeutic applications.
- Untapped Market Potential in Developing Regions: The neurotrophins market has significant growth potential in developing regions. Improving healthcare systems in regions such as Asia-Pacific, Latin America, and Africa are increasing the demand for advanced treatments for neurological diseases. According to the WHO, the prevalence of dementia in the Asia-Pacific region is expected to rise by 90% by 2050, making it one of the fastest-growing markets for neurological treatments. The growing geriatric population and rising awareness of neurodegenerative diseases are driving this demand. Pharmaceutical companies are increasingly focusing on these regions, taking advantage of improved healthcare infrastructure and government support for healthcare
- Neurotrophin in regenerative medicine: Neurotrophins are increasingly identified as likely candidates for applications in regenerative medicine, particularly in neurology, thus enabling the treatment of neurological damage and disorders. Examples include NGF and BDNF that positively affect neurogenesis and help regenerate neurons. Potential treatments in regenerative medicine include spinal cord injuries, stroke, and traumatic brain injuries. Neurotrophins have the ability to promote neuronal growth, survival in such conditions, thus bringing considerable opportunities in the field of regenerative medicine, which has long sought solutions to severe, hence currently untreatable neurological disorders. Since further research continues to yield positive results, neurotrophins are going to play a pivotal role in the future of neurological regeneration, creating new markets for these therapies. improvements to expand their presence. Companies that can effectively introduce neurotrophin-based treatments in these regions can tap into a largely underserved market, offering a significant opportunity for market expansion.
- Collaborations & Partnerships: Collaborations and partnerships are crucial for speeding up the development and commercialization of neurotrophin-based therapies. Strategic collaborations between pharmaceutical companies, biotechnology firms, and academic institutions provide opportunities for resource sharing, risk reduction, and access to specialized expertise. Partnerships are particularly important in the neurotrophins market, where the development of effective therapies requires advanced knowledge in gene therapy, drug delivery systems, and clinical research. This trend will allow companies to tap into novel neurotrophin applications, such as in gene therapy and precision medicine, thus creating opportunities for growth and expansion. Collaborative efforts can streamline the development process, enhance innovation, and bring new treatments to market faster.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Neurotrophins Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Neurotrophins Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Neurotrophins Market is expected to register a CAGR of 7% from 2025-2031.
The major driving factors supporting the Neurotrophins market growth are - Increased Neurological disorders globally, Advances in Biotechnology, and Aging Population
Key future trends in the Neurotrophins Market are - Targeted Therapies and Integration with Gene Therapy
Key companies in the Neurotrophins Market are- R&D Systems
, Antigenix America Inc.
, Johnson?Johnson
, PeproTech
, FibroGen
, Merck Serono
, Janssen Biotech, Inc.,
, GE Healthcare
, Scil Proteins GmbH
, Lonza Groups
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Neurotrophins Market - By Product Type
1.3.2 Neurotrophins Market - By Application
1.3.3 Neurotrophins Market - By End-user
1.3.4 Neurotrophins Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. NEUROTROPHINS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. NEUROTROPHINS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NEUROTROPHINS MARKET - GLOBAL MARKET ANALYSIS
6.1. NEUROTROPHINS - GLOBAL MARKET OVERVIEW
6.2. NEUROTROPHINS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. NEUROTROPHINS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. NERVE GROWTH FACTOR
7.3.1. Overview
7.3.2. Nerve Growth Factor Market Forecast and Analysis
7.4. BRAIN-DERIVED NEUROTROPHIC FACTOR
7.4.1. Overview
7.4.2. Brain-Derived Neurotrophic Factor Market Forecast and Analysis
7.5. DEHYDROEPIANDROSTERONE SULFATE
7.5.1. Overview
7.5.2. Dehydroepiandrosterone Sulfate Market Forecast and Analysis
7.6. OTHER
7.6.1. Overview
7.6.2. Other Market Forecast and Analysis
8. NEUROTROPHINS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ALZHEIMER'S DISEASE
8.3.1. Overview
8.3.2. Alzheimer's Disease Market Forecast and Analysis
8.4. AMYOTROPHIC LATERAL SCLEROSIS
8.4.1. Overview
8.4.2. Amyotrophic Lateral Sclerosis Market Forecast and Analysis
8.5. PARKINSON'S DISEASE
8.5.1. Overview
8.5.2. Parkinson's Disease Market Forecast and Analysis
8.6. OTHER
8.6.1. Overview
8.6.2. Other Market Forecast and Analysis
9. NEUROTROPHINS MARKET - REVENUE AND FORECASTS TO 2028 - END-USER
9.1. OVERVIEW
9.2. END-USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. DIAGNOSTIC CENTERS
9.4.1. Overview
9.4.2. Diagnostic Centers Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. NEUROTROPHINS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Neurotrophins Market Overview
10.1.2 North America Neurotrophins Market Forecasts and Analysis
10.1.3 North America Neurotrophins Market Forecasts and Analysis - By Product Type
10.1.4 North America Neurotrophins Market Forecasts and Analysis - By Application
10.1.5 North America Neurotrophins Market Forecasts and Analysis - By End-user
10.1.6 North America Neurotrophins Market Forecasts and Analysis - By Countries
10.1.6.1 Canada Neurotrophins Market
10.1.6.1.1 Canada Neurotrophins Market by Product Type
10.1.6.1.2 Canada Neurotrophins Market by Application
10.1.6.1.3 Canada Neurotrophins Market by End-user
10.1.6.2 Mexico Neurotrophins Market
10.1.6.2.1 Mexico Neurotrophins Market by Product Type
10.1.6.2.2 Mexico Neurotrophins Market by Application
10.1.6.2.3 Mexico Neurotrophins Market by End-user
10.1.6.3 US Neurotrophins Market
10.1.6.3.1 US Neurotrophins Market by Product Type
10.1.6.3.2 US Neurotrophins Market by Application
10.1.6.3.3 US Neurotrophins Market by End-user
10.2. EUROPE
10.2.1 Europe Neurotrophins Market Overview
10.2.2 Europe Neurotrophins Market Forecasts and Analysis
10.2.3 Europe Neurotrophins Market Forecasts and Analysis - By Product Type
10.2.4 Europe Neurotrophins Market Forecasts and Analysis - By Application
10.2.5 Europe Neurotrophins Market Forecasts and Analysis - By End-user
10.2.6 Europe Neurotrophins Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Neurotrophins Market
10.2.6.1.1 Germany Neurotrophins Market by Product Type
10.2.6.1.2 Germany Neurotrophins Market by Application
10.2.6.1.3 Germany Neurotrophins Market by End-user
10.2.6.2 France Neurotrophins Market
10.2.6.2.1 France Neurotrophins Market by Product Type
10.2.6.2.2 France Neurotrophins Market by Application
10.2.6.2.3 France Neurotrophins Market by End-user
10.2.6.3 Italy Neurotrophins Market
10.2.6.3.1 Italy Neurotrophins Market by Product Type
10.2.6.3.2 Italy Neurotrophins Market by Application
10.2.6.3.3 Italy Neurotrophins Market by End-user
10.2.6.4 Spain Neurotrophins Market
10.2.6.4.1 Spain Neurotrophins Market by Product Type
10.2.6.4.2 Spain Neurotrophins Market by Application
10.2.6.4.3 Spain Neurotrophins Market by End-user
10.2.6.5 United Kingdom Neurotrophins Market
10.2.6.5.1 United Kingdom Neurotrophins Market by Product Type
10.2.6.5.2 United Kingdom Neurotrophins Market by Application
10.2.6.5.3 United Kingdom Neurotrophins Market by End-user
10.2.6.6 Rest of Europe Neurotrophins Market
10.2.6.6.1 Rest of Europe Neurotrophins Market by Product Type
10.2.6.6.2 Rest of Europe Neurotrophins Market by Application
10.2.6.6.3 Rest of Europe Neurotrophins Market by End-user
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Neurotrophins Market Overview
10.3.2 Asia-Pacific Neurotrophins Market Forecasts and Analysis
10.3.3 Asia-Pacific Neurotrophins Market Forecasts and Analysis - By Product Type
10.3.4 Asia-Pacific Neurotrophins Market Forecasts and Analysis - By Application
10.3.5 Asia-Pacific Neurotrophins Market Forecasts and Analysis - By End-user
10.3.6 Asia-Pacific Neurotrophins Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Neurotrophins Market
10.3.6.1.1 Australia Neurotrophins Market by Product Type
10.3.6.1.2 Australia Neurotrophins Market by Application
10.3.6.1.3 Australia Neurotrophins Market by End-user
10.3.6.2 China Neurotrophins Market
10.3.6.2.1 China Neurotrophins Market by Product Type
10.3.6.2.2 China Neurotrophins Market by Application
10.3.6.2.3 China Neurotrophins Market by End-user
10.3.6.3 India Neurotrophins Market
10.3.6.3.1 India Neurotrophins Market by Product Type
10.3.6.3.2 India Neurotrophins Market by Application
10.3.6.3.3 India Neurotrophins Market by End-user
10.3.6.4 Japan Neurotrophins Market
10.3.6.4.1 Japan Neurotrophins Market by Product Type
10.3.6.4.2 Japan Neurotrophins Market by Application
10.3.6.4.3 Japan Neurotrophins Market by End-user
10.3.6.5 South Korea Neurotrophins Market
10.3.6.5.1 South Korea Neurotrophins Market by Product Type
10.3.6.5.2 South Korea Neurotrophins Market by Application
10.3.6.5.3 South Korea Neurotrophins Market by End-user
10.3.6.6 Rest of Asia-Pacific Neurotrophins Market
10.3.6.6.1 Rest of Asia-Pacific Neurotrophins Market by Product Type
10.3.6.6.2 Rest of Asia-Pacific Neurotrophins Market by Application
10.3.6.6.3 Rest of Asia-Pacific Neurotrophins Market by End-user
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Neurotrophins Market Overview
10.4.2 Middle East and Africa Neurotrophins Market Forecasts and Analysis
10.4.3 Middle East and Africa Neurotrophins Market Forecasts and Analysis - By Product Type
10.4.4 Middle East and Africa Neurotrophins Market Forecasts and Analysis - By Application
10.4.5 Middle East and Africa Neurotrophins Market Forecasts and Analysis - By End-user
10.4.6 Middle East and Africa Neurotrophins Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Neurotrophins Market
10.4.6.1.1 South Africa Neurotrophins Market by Product Type
10.4.6.1.2 South Africa Neurotrophins Market by Application
10.4.6.1.3 South Africa Neurotrophins Market by End-user
10.4.6.2 Saudi Arabia Neurotrophins Market
10.4.6.2.1 Saudi Arabia Neurotrophins Market by Product Type
10.4.6.2.2 Saudi Arabia Neurotrophins Market by Application
10.4.6.2.3 Saudi Arabia Neurotrophins Market by End-user
10.4.6.3 U.A.E Neurotrophins Market
10.4.6.3.1 U.A.E Neurotrophins Market by Product Type
10.4.6.3.2 U.A.E Neurotrophins Market by Application
10.4.6.3.3 U.A.E Neurotrophins Market by End-user
10.4.6.4 Rest of Middle East and Africa Neurotrophins Market
10.4.6.4.1 Rest of Middle East and Africa Neurotrophins Market by Product Type
10.4.6.4.2 Rest of Middle East and Africa Neurotrophins Market by Application
10.4.6.4.3 Rest of Middle East and Africa Neurotrophins Market by End-user
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Neurotrophins Market Overview
10.5.2 South and Central America Neurotrophins Market Forecasts and Analysis
10.5.3 South and Central America Neurotrophins Market Forecasts and Analysis - By Product Type
10.5.4 South and Central America Neurotrophins Market Forecasts and Analysis - By Application
10.5.5 South and Central America Neurotrophins Market Forecasts and Analysis - By End-user
10.5.6 South and Central America Neurotrophins Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Neurotrophins Market
10.5.6.1.1 Brazil Neurotrophins Market by Product Type
10.5.6.1.2 Brazil Neurotrophins Market by Application
10.5.6.1.3 Brazil Neurotrophins Market by End-user
10.5.6.2 Argentina Neurotrophins Market
10.5.6.2.1 Argentina Neurotrophins Market by Product Type
10.5.6.2.2 Argentina Neurotrophins Market by Application
10.5.6.2.3 Argentina Neurotrophins Market by End-user
10.5.6.3 Rest of South and Central America Neurotrophins Market
10.5.6.3.1 Rest of South and Central America Neurotrophins Market by Product Type
10.5.6.3.2 Rest of South and Central America Neurotrophins Market by Application
10.5.6.3.3 Rest of South and Central America Neurotrophins Market by End-user
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. NEUROTROPHINS MARKET, KEY COMPANY PROFILES
12.1. R AND D SYSTEMS
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ANTIGENIX AMERICA INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. JOHNSON AND JOHNSON
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. PEPROTECH
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. FIBROGEN
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MERCK SERONO
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. JANSSEN BIOTECH, INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. GE HEALTHCARE
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SCIL PROTEINS GMBH
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. LONZA GROUPS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. R and D Systems
2. Antigenix America Inc.
3. Johnson and Johnson
4. PeproTech
5. FibroGen
6. Merck Serono
7. Janssen Biotech, Inc.
8. GE Healthcare
9. Scil Proteins GmbH
10. Lonza Groups
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For